Stoke Therapeutics Comes Out of Seed Mode With $40M and Ex-Sarepta CEO at Its Helm Post author:Sam Post published:January 3, 2018 Post category:BioPharma The Series A round was entirely funded by founding investor Apple Tree Partners. Source: BioSpace You Might Also Like Amgen to Build New $300M Facility After Tax Changes February 1, 2018 Pernix Takes the Ax to 22% of Workforce in Reorg January 4, 2018 Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments June 11, 2017
Ensysce Biosciences Inc. Attending NIH Conference: Cutting Edge Science Meeting Series To End The Opioid Crisis: Development Of Safe, Effective, Non-Addictive Pain Treatments June 11, 2017
